Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?
Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update? simplywall.st
Covered in this story
Analyst targets on Amgen
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 47 stories mentioning Amgen, the earliest published 2 Jul 2026.
Summary aggregated from simplywall.st's public RSS feed. The full reporting belongs to simplywall.st — please read it on their site.